Yashraj Biotechnology Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Yashraj Biotechnology Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $661.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Yashraj Biotechnology Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $661.5K Trade | TransData Nexus

Yashraj Biotechnology Limited

Indian Pharmaceutical Exporter · Medical Devices & Diagnostics Specialist · $661.5K Total Trade · DGFT Verified

Yashraj Biotechnology Limited is an Indian pharmaceutical exporter with a total trade value of $661.5K across 2 products in 2 therapeutic categories. Based on 83 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Diagnostic ($638.7K), Plasma ($22.7K), .

Yashraj Biotechnology Limited — Export Portfolio & Destination Treemap

Yashraj Biotechnology Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Yashraj Biotechnology Limited? — Company Overview & Market Position

Yashraj Biotechnology Limited (YBL) is a public limited company incorporated on May 6, 1999, in Navi Mumbai, Maharashtra, India. The company specializes in the biotechnology sector, focusing on in vitro diagnostics (IVD) and preclinical drug discovery services. YBL is registered under the Corporate Identification Number (CIN) U73100MH1999PLC119769.

The authorized capital of YBL is ₹80 million, with a paid-up capital of ₹49.55 million. As of December 2024, the company employed approximately 275 professionals. The registered office is located at C-232, TTC Industrial Area MIDC, Navi Mumbai, Maharashtra 400705, India. YBL's official website is www.yashraj.com.

What Does Yashraj Biotechnology Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Diagnostic$638.7K 2Plasma$22.7K

Yashraj Biotechnology Limited Therapeutic Categories — 2 Specializations

Product Portfolio — Top 2 by Export Value

Yashraj Biotechnology Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Diagnostic	Medical Devices & Diagnostics	$638.7K	79	3.5%	9
2	Plasma	Other	$22.7K	4	0.8%	13

Yashraj Biotechnology Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $661.5K. The top category is Medical Devices & Diagnostics (96.6% of portfolio), followed by Other (3.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Yashraj Biotechnology Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

YBL operates state-of-the-art manufacturing facilities in Mumbai, India, adhering to ISO 13485 and ISO 9001 standards. These facilities specialize in the production of native and recombinant antigens, monoclonal and polyclonal antibodies, and induced pluripotent stem cells (iPSCs). The company has expanded its global reach by establishing subsidiaries in Germany and the USA to ensure a robust supply chain and exceptional customer service.

3Key Leadership

The leadership team at YBL comprises individuals with diverse expertise guiding the company's strategic direction. Key executives include:

Mr. Arvind Bhanushali: Director
Dr. Haseeb Drabu: Director
Dr. Subhash Mundra: Director
Shri. Dinesh Kumar Jain: Managing Director
Mr. Sanjay Singh: Director
Dr. Himanshu Mody: Director

These leaders are committed to driving innovation and growth within the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Yashraj Biotechnology Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

YBL's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's focus on in vitro diagnostics and preclinical drug discovery services suggests potential engagement with these markets. However, specific regulatory filings, approvals, and market access statuses are not provided in the available information.

2Emerging Markets

YBL has expanded its global reach by establishing subsidiaries in Germany and the USA, indicating a strategic focus on emerging markets. The company's expertise in preclinical drug discovery and IVD services positions it to penetrate markets in Africa, Latin America, and Southeast Asia. While specific WHO prequalification status is not mentioned, YBL's commitment to quality and innovation supports its potential for access to these regions.

3Geographic Strategy

YBL's geographic strategy includes establishing subsidiaries in Germany and the USA, enhancing its global footprint and supply chain robustness. This diversification reduces concentration risk and aligns with the company's strategic direction to serve a broader international market. The focus on both developed and emerging markets reflects a balanced approach to growth and market penetration.

Yashraj Biotechnology Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding YBL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. Given the company's focus on in vitro diagnostics and preclinical drug discovery services, it is plausible that YBL engages with the FDA for relevant approvals. However, without explicit information, a comprehensive assessment cannot be made.

2WHO & EU GMP

The available information does not specify whether YBL holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The company's adherence to ISO 13485 and ISO 9001 standards indicates a commitment to quality management systems. However, without explicit details on WHO and EU GMP certifications, a definitive assessment cannot be provided.

3CDSCO & Indian Regulatory

Specific details regarding YBL's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), state drug controller approvals, and export No Objection Certificates (NOCs) are not available in the provided sources. Given the company's operations in the biotechnology sector, it is likely that YBL complies with relevant Indian regulatory requirements. However, without explicit information, a comprehensive assessment cannot be made.

Yashraj Biotechnology Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

YBL operates in the competitive biotechnology sector, focusing on in vitro diagnostics and preclinical drug discovery services. While specific competitors are not identified in the available sources, the company's global reach and adherence to quality standards position it favorably in the market. The establishment of subsidiaries in Germany and the USA indicates a strategic approach to competing in international markets.

2Key Differentiators

YBL's key differentiators include its extensive experience in the IVD sector, specializing in native and recombinant antigens, monoclonal and polyclonal antibodies, and iPSCs. The company's commitment to quality is demonstrated by its adherence to ISO 13485 and ISO 9001 standards. The establishment of subsidiaries in Germany and the USA enhances its global presence and supply chain capabilities.

3Strategic Position

YBL's current strategic direction focuses on in vitro diagnostics and preclinical drug discovery services, with an emphasis on innovation and quality. The company's expansion into stem cell research and the establishment of international subsidiaries reflect a forward-looking approach to growth and market diversification. Future outlooks are not explicitly detailed in the available sources.

Buyer Due Diligence Brief — Evaluating Yashraj Biotechnology Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

YBL's track record in the biotechnology sector is characterized by its specialization in IVD and preclinical drug discovery services. The company's export volume and consistency are not explicitly detailed in the available sources. However, its adherence to international quality standards and the establishment of global subsidiaries suggest reliability and a commitment to meeting customer needs.

2Certifications to Verify

Importers should verify the following certifications when considering YBL as a supplier:

FDA Approval: To ensure compliance with U.S. regulatory standards. Verification can be done through the FDA's official website or by contacting YBL directly.

WHO-GMP Certification: To confirm adherence to World Health Organization Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting YBL directly.

Frequently Asked Questions — Yashraj Biotechnology Limited

How many pharmaceutical products does Yashraj Biotechnology Limited export from India?

Yashraj Biotechnology Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Diagnostic ($638.7K), Plasma ($22.7K). Total export value is $661.5K.

What is Yashraj Biotechnology Limited's total pharmaceutical export value?

Yashraj Biotechnology Limited's total pharmaceutical export value is $661.5K, based on 83 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Yashraj Biotechnology Limited cover?

Yashraj Biotechnology Limited exports across 2 therapeutic categories. The largest are Medical Devices & Diagnostics (96.6%, 1 products), Other (3.4%, 1 products).

Get Full Yashraj Biotechnology Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.